Selected probiotics
A six-strain blend targeting 25 billion CFU per sachet at expiry, subject to final stability confirmation.
Coming Christmas 2026
Prebiotic + Probiotic with Low-Iodine Borneo Sea Moss
A dairy-free, casein-free chocolate cocoa powder sachet in development for children aged 5–12, combining selected probiotics, prebiotic fibre, algal DHA/EPA, vitamin C and low-iodine Borneo sea moss extract.
Sold out for now. Join the early interest list for launch updates.
7982 people have shown interest in this product
Under development. Final formulation, claims, registration pathway, label and launch timing remain subject to regulatory and stability confirmation.
View full artwork
Development progress
Development stages and target timing may change following final test results, regulatory review, manufacturing readiness and certification requirements.
The formulation concept
The formula is being developed around six complementary components, selected for a practical daily nutrition routine.
A six-strain blend targeting 25 billion CFU per sachet at expiry, subject to final stability confirmation.
A soluble prebiotic fibre chosen to complement the probiotic blend and support a microbiome-focused routine.
Plant-based omega-3 from algae, avoiding fish and shellfish sources.
An established nutrient included as part of the broader daily nutrition formulation.
A low-iodine marine botanical extract requiring iodine, heavy-metal and microbiology controls.
A dairy-free and casein-free powder format intended to make consistency easier for children and parents.
Target probiotic architecture
These are development targets, not the final registered label. Species, strains, quantities and CFU-at-expiry statements remain subject to final manufacturing verification and stability data.
Product story and formulation artwork
Select any image to open the full-resolution artwork. Product and marketing statements shown in development artwork remain subject to regulatory review and final substantiation.
A complementary routine
The products are designed around different nutritional priorities. They are not substitutes for one another, and combined use should be reviewed against the child's full diet, existing supplements and professional advice.
Explore Argenix NeuroGlowArgenix NeuroGlow
Argenix Biotrix Junior
Research context
Small clinical studies have explored certain individual probiotic strains in autistic children. They do not establish that Biotrix Junior treats autism or that this multi-ingredient formula will reproduce study outcomes.
Frequently asked questions
Details will be updated as the formulation, registration pathway and production validation are finalized.
No. It is in development, with a target launch around Christmas 2026. Timing may change following regulatory or stability review.
The current concept is intended for children aged 5–12 years. Final age guidance must follow the approved product label.
That is the development specification. Final allergen and free-from statements will be confirmed from the finished formulation and manufacturing controls.
The formulas have different nutritional focuses. Before combining supplements for a child, review the complete ingredient and nutrient totals with an appropriate healthcare professional.
No. It is being developed as a nutritional supplement and is not intended to diagnose, treat, cure or prevent autism, ADHD, GDD, speech delay or any medical condition.
The sea moss component is intended as a controlled marine botanical, not an iodine booster. Final iodine specifications and quality testing must be verified before launch.
Be first in line
Receive launch updates, formulation news and availability information. Joining is not a purchase or reservation.
This product is under development. Final formulation, registration pathway, label text, ingredient availability, quality specifications and launch date are subject to regulatory review, manufacturing confirmation and stability testing. Biotrix Junior is a nutritional supplement and is not intended to diagnose, treat, cure or prevent disease.